The present study was performed as a retrospective analysis of the role of pretransplant splenectomy to determine the incidence of late bacterial infections, acute and chronic graftversus-host disease (GVHD), relapse, and survival among 358 patients receiving HLA-identical marrow grafts for chronic myelogenous leukemia. Sixty-eight (19%) of the 358 patients had undergone splenectomy before transplantation. There was a trend towards more grade Il-IV acute GVHD among splenectomized patients, but this was not significant in the multivariate analysis. The incidence of chronic GVHD was similar for splenectomized and nonsplenectomized patients. Late infectious complications did not significantly differ between splenectomized and control patients (rates per patient year were 0.16 and 0.14, respectively). The overall risk of leukemic relapse was significantly increased for splenectomized patients (56% Y 32% HE VALUE OF splenectomy or splenic irradiation preceding allogeneic marrow transplantation for chronic myelogenous leukemia (CML) has been controversial. Some studies suggest that splenectomy might be of benefit in terms of tumor eradication"3 or hematologic recovery.'~' Other reports indicate that splenectomy has no impact on relapse and survival.'"' A recent randomized trial of patients with CML transplanted in first chronic phase showed that splenic irradiation did not modulate relapse or survival." This trial and other reports suggest that the incidence and seventy of acute graft-versus-host disease (GVHD) might be increased in patients with pretransplant splenectomy or splenic irradiafindings8 Several investigators report that splenectomy had no influence on the incidence of infectious complications occurring in the early posttransplant p e r i~d .~.~ In contrast, patients who develop functional asplenia associated with extensive chronic GVHD do have an increased risk for late bacterial infections.14 The present study was performed as a retrospective analysis of the role of pretransplant splenectomy among 358 con-T tion6,7,9,11-13. , h owever, other studies do not confirm these secutive patients receiving HLA-genotypically identical marrow grafts for CML to determine the incidence of late infections, GVHD, and relapse. We found that splenectomy did not increase late infections and had no significant effect on the incidence or severity of acute or chronic GVHD. However, both splenectomy and splenomegaly were associated with an increased risk of recurrent leukemia.
The present study was performed as a retrospective analysis of the role of pretransplant splenectomy to determine the incidence of late bacterial infections, acute and chronic graftversus-host disease (GVHD), relapse, and survival among 358 patients receiving HLA-identical marrow grafts for chronic myelogenous leukemia. Sixty-eight (19%) of the 358 patients had undergone splenectomy before transplantation. There was a trend towards more grade Il-IV acute GVHD among splenectomized patients, but this was not significant in the multivariate analysis. The incidence of chronic GVHD was similar for splenectomized and nonsplenectomized patients. Late infectious complications did not significantly differ between splenectomized and control patients (rates per patient year were 0.16 and 0.14, respectively). The overall risk of leukemic relapse was significantly increased for splenectomized patients (56% Y 32% HE VALUE OF splenectomy or splenic irradiation preceding allogeneic marrow transplantation for chronic myelogenous leukemia (CML) has been controversial. Some studies suggest that splenectomy might be of benefit in terms of tumor eradication"3 or hematologic recovery.'~' Other reports indicate that splenectomy has no impact on relapse and survival.'"' A recent randomized trial of patients with CML transplanted in first chronic phase showed that splenic irradiation did not modulate relapse or survival." This trial and other reports suggest that the incidence and seventy of acute graft-versus-host disease (GVHD) might be increased in patients with pretransplant splenectomy or splenic irradiafindings8 Several investigators report that splenectomy had no influence on the incidence of infectious complications occurring in the early posttransplant p e r i~d .~.~ In contrast, patients who develop functional asplenia associated with extensive chronic GVHD do have an increased risk for late bacterial infections. 14 The present study was performed as a retrospective analysis of the role of pretransplant splenectomy among 358 con-T tion6,7,9,11-13. , h owever, other studies do not confirm these for controls, P = .001) and control patients with splenomegaly (P < .OOOl). Splenectomy and splenomegaly remained significant and independent hazards for relapse in the multivariate analysis (hazard ratio [HR], 1.82, P = .029; and HR, 1.49, P = .002; respectively). Relapse was also increased in patients with advanced disease (HR. 2.95; P = .0001), in patients with T-cell-depleted marrow (HR. 4.51; P = .0001), and in the female donor and male recipient combination (HR. 1.74; P = .044). Patients with splenectomy had an increased overall mortality (HR. 1.18), but this was not statistically significant in the multivariate analysis. In summary, our study showed no significant influence of splenectomy on late posttransplant infections, acute or chronic GVHD, or overall survival. There was no evidence that splenectomy decreased recurrence of chronic myelogenous leukemia.
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secutive patients receiving HLA-genotypically identical marrow grafts for CML to determine the incidence of late infections, GVHD, and relapse. We found that splenectomy did not increase late infections and had no significant effect on the incidence or severity of acute or chronic GVHD. However, both splenectomy and splenomegaly were associated with an increased risk of recurrent leukemia.
MATERIALS AND METHODS

Patients.
Between April 1974 and November 1988,440 consecutive patients with CML received an allogeneic marrow graft from an HLA-identical sibling in Seattle. Eighty-two patients had to be excluded from the analysis because their spleen status at the time of transplant was not recorded. Sixty-eight (19%) of the 358 eligible patients had undergone splenectomy before transplantation ( Table  1) . The splenectomy and the control group were well matched for age, gender, marrow cell dose, and care in laminar airflow (LAF) rooms. Of the 358 patients, only 4 splenectomized patients and 18 controls were children less than 16 years of age. The splenectomy group had a significantly longer history of disease before transplantation than the control group and comprised significantly more patients with advanced-stage CML. Most patients in the splenectomy group received methotrexate (MTX) alone for GVHD prophylaxis, whereas the majority of control patients had received transplants in more recent years and received prophylaxis with MTX + cyclosporine A (CSP). The percentages of patients receiving T-cell depletion for GVHD prophylaxis were equal for splenectomized and control patients. Control patients more frequently received intravenous Ig prophylaxis.
The indications for splenectomy and the spleen size of control patients are given in Table 2 . The indications for splenectomy were unknown in 44 of the 68 patients. The spleen was enlarged at the time of transplant in 134 (46%) of the 290 control patients.
Transplantation regimen and supportive care. Transplant and GVHD regimens are shown in Table 1 . The day of marrow infusion was designated as 0. Trimethoprim-sulfamethoxazole was administered for prevention of Pneumocystis carinii infection until day 120 posttransplant. In patients with chronic GVHD, trimethoprim-sulfamethoxazole prophylaxis was continued during immunosuppressive therapy. Patients received prophylactic Ig as previously described." All patients in LAF isolation received oral nonabsorbable antibiotics Abbreviations: BMT, bone marrow transplantation; CSP, cyclosporine A; Cy, cyclophosphamide; DMM, dimethyl myleran; FTBI, fractionated total body irradiation; HFTBI, hyperfractionated total body irradiation; IVlg, intravenous lg; LAF, laminar airflow isolation; MTX, methotrexate; TBI, total body irradiation.
Based on Wilcoxon rank sum tests. for gastrointestinal decontamination, as previously reported.I6," Sixteen percent of evaluable splenectomized patients and 1 1 % of evaluable control patients received oral penicillin prophylaxis beyond day 100 after marrow transplantation ( P = .46). Definition and evaluation of infections. Infections occurring beyond day 100 posttransplant were designated late. infections. Infections were classified as previously de~cribed.'~ Bacteremia was de-2029 fined by one or more positive blood cultures associated with fever as the only sign of infection or by more than one positive blood cultures with the same organism regardless of any sign of infection.
Septicemia was indicated by one or more positive blood cultures for any organism associated with either hypotension or documented local infection caused by the same organism recovered from the blood. Local infection was assessed by isolation of organisms from a site associated with signs or symptoms of infection, if the organisms recovered were capable of causing the clinical findings. Clinical local infection was defined by the presence of signs and symptoms at an infected site in the absence of microbiologic confirmation. Infections of the oral cavity and the upper respiratory tract as well as herpes virus infections were excluded from the analysis. Cytomegalovirus (CMV) disease was indicated by tissue evidence of virus with associated signs and symptoms of infection.
Grading of GVHD. The assessment and grading of acute and chronic GVHD have been previously de~cribed.".'~ Grade I acute GVHD was judged to be mild, grade I1 was judged to be moderate, grade 111 was judged to be severe, and grade IV was judged to be life-threatening GVHD.
Staristicat analysis. Demographic and clinical characteristics of splenectomy and control patients were compared using x' or Wilcoxon rank-sum tests.
Rates of late infection were measured by the incidence density (ID), which is the ratio of the number of infection episodes and the amount of evaluation time accrued by the candidate population (expressed as patient days at risk of infection). Patients were regarded to be at risk of infection if they were alive without relapse. The incidence density ratio (IDR), a ratio of two IDS, was used to assess the relative effects of splenectomy on incidence rates."." A statistical test was performed to test whether the IDS of the two groups were similar (ie, IDR = 1). Because we hypothesized that splenectomy patients would have a higher incidence of infections than would nonsplenectomized patients (IDR > l), one-sided P values were computed using the binominal probability distribution.
The incidence of acute and chronic GVHD, overall survival, and relapse of CML were estimated using the Kaplan-Meier method," and differences in these outcomes in Splenectomy and nonsplenectomized patients were compared using the logrank test.23
Because some pretransplant characteristics and transplant regimens differed between the two groups, Cox proportional hazard regressionz4 was performed to evaluate the effects of splenectomy on acute and chronic GVHD, relapse, and survival adjusted for these factors. Covariates were selected for each model based on prior evidence of their effect on the outcomes of interest. These covariates were included as potentially confounding factors regardless of the significance level. In multivariate analyses among controls only, spleen size was modeled as a group linear variable using the following coding: 0, spleen not palpable; 1, tip palpable; 2, spleen 4 to 8 cm under costal margin (UCM); 3, spleen 1 8 cm UCM. By including spleen size in this manner, we assume an approximately linear relationship between these categories and the endpoint (eg, risk of relapse). Thus, the hazard ratio (HR) estimates represent the increased (or decreased) risk associated with a given category compared with that of the next smaller spleen size category,
RESULTS
Engraftment.
The Kaplan Meier estimate of median times to recovery of absolute neutrophil counts of 2OO/pL, 500/pL, and I,OOo/pL were 17, 17, and 19 days in splenectomized patients versus 22, 23, and 27 days in control patients ( P = .074, P = .0001, and P = .0001, respectively). The Kaplan-Meier estimate of median time to recovery of a platelet count of 50,OOO/pL was 35 days in the splenectomy group and 42 days in the control group ( P = .102).
GVHD. Splenectomy was a risk factor for the development of acute GVHD in the univariate analysis. The probability of developing grade 11-IV acute GVHD was 50% for splenectomized patients and 38% for control patients ( P = .024). Cox regression analysis showed an increased hazard ratio of grade 11-IV acute GVHD (HR, 1.52), but this did not reach statistical significance ( P = .058). The risk of grade 11-IV acute GVHD was decreased with MTX + CSP prophylaxis (HR, 0.90; P = .725), intravenous Ig prophylaxis (HR, 0.78; P = .396), and T-cell depletion (HR, 0.71; P = .287), and increased for the combination of a female donor and male recipient (HR, 1.27; P = .219) and increasing patient age (HR, 1.02; P = ,090).
There was no difference in the incidence of chronic GVHD between splenectomized and control patients. In the multivariate analysis, T-cell depletion was associated with a reduction of chronic GVHD (HR, 0.44; P = .074), whereas the female donor and male recipient combination (HR, 1.50; P = ,075). preceding acute GVHD (HR, 1.37; P = . l29), and increasing patient age (HR, 1.02; P = .081) were associated with an increased risk of chronic GVHD.
Infection. Late infectious complications did not significantly differ between splenectomized and control patients ( Table 3 ). The respective rates of overall late infections per patient year were 0.16 for the splenectomized and 0.14 for the control patients.
Relapse. As shown in Fig 1, the overall risk of leukemic relapse by Kaplan-Meier analysis was significantly increased for splenectomized patients (56% for splenectomized patients v 32% for control patients, P = .001). Among patients receiving transplants in chronic phase, relapse rates were 32% for splenectomized and 22% for control patients ( P = ,325); among patients receiving transplants in advancedstage CML, the risk of relapse was 75% for splenectomized and 50% for control patients, respectively ( P = .061). As shown in Table 4 , splenectomy remained a significant hazard for relapse in the multivariate analysis (HR, 1.82; P = .029). Splenomegaly in control patients was also a significant risk factor for relapse in the univariate ( P < .0001; Fig 2) and the multivariate analysis (HR, 1.49; P = .002; Table 4 ). Relapse was also increased in patients with advanced-stage KALHS ET AL malignancy (HR, 2.95; P = .OOOl), in patients receiving Tcell-depleted marrow (HR, 4.51; P = .OOOl), and in female donor and male recipient combinations (HR, 1.74; P = .044).
Survival. Survival was significantly decreased in pa-
tients with advanced-stage leukemia (HR, 2.19; P = .Owl),
T-cell depletion (HR, 1.78; P = .Oo4), acute GVHD (HR, 1.62; P = .001), and a female donor and male recipient combination (HR, 1.46; P = ,015). MTX + CSP prophylaxis was associated with significantly improved survival (HR, 0.65; P = .005). Splenectomized patients and patients with splenomegaly had an increased mortality (HR, 1.18 and 1.16, respectively), but this was not statistically significant in the multivariate analysis.
DISCUSSION
The present study investigates whether splenectomy in patients undergoing allogeneic transplantation for CML has an impact on posttransplant events with special regard to late infectious complications, acute and chronic GVHD, relapse, and survival.
It is well recognized that children are at increased risk for bacterial infections after ~p l e n e c t o m y .~~.~~ Patients undergoing spkenectomy for malignancy appear to be at higher risk for infection than patients undergoing splenectomy for trauma, presumably due to the additional immunosuppression of ma1ignan~y.z~ From the literature there is no evidence that splenectomy increases the risk of early infections after marrow grafting.'.' In the present study, we investigated the risk of splenectomy for infections occurring beyond day 100 after marrow grafting. Because of the limited number of children in this study, we could not determine infection rates in the pediatric splenectomy population. In the cohort of adults, we found no adverse effect of splenectomy on late posttransplant infections. There was also no significant dif- ference with regard to the individual site or type of infection for the splenectomy and the control group. This observation clarifies other studies reporting that patients who develop functional asplenia associated with extensive chronic GVHD have an increased risk for late bacterial infection^.'^ It would appear that chronic GVHD and the associated immunosuppressive therapy, rather than asplenia, are the major deterrninants of late infection in allograft recipients.
Prior studies report that the spleen may modulate the severity and incidence of acute GVHD.6*739,""3 In the present study, we too noted that splenectomy was associated with an increased hazard for all grades of acute GVHD, but this did not reach statistical significance when adjusted for other factors influencing development of GVHD. It cannot be ruled out that the increased risk of GVHD in splenectomized patients was rather due to differences in the GVHD prophylaxis than to splenectomy by itself because more patients in the control group had received CSP-containing regimens.
Initial reports suggested that splenectomy before bone marrow transplantation might reduce tumor load in patients with CML.'-3 Subsequent studies have shown that splenectomy or splenic irradiation did not decrease the risk of relapse in CML In the present study, splenectomy was associated with an increased risk of relapse. Splenectomy remained an independent hazard for relapse after adjusting for established risk factors in a multivariate analysis. The most likely explanation for the increased relapse rate among splenectomized patients is that the need for splenectomy by itself indicated a progressive stage of the disease. Relapse rates were equal when splenectomized patients were compared with control patients with extensive splenomegaly, further suggesting that splenectomy might be a surrogate for splenomegaly.
More rapid hematologic recovery was observed in the splenectomized patients. Prior studies have reported faster neutrophil and platelet recovery and decreased platelet transfusion requirements with splenectomy.' Thus, for highly selected individuals with massive splenomegaly, refractoriness to random donor platelets, and limited access to HLA-compatible platelet donors, pretransplant splenectomy may be used to improve subsequent supportive care. Furthermore, splenectomy might facilitate engraftment in patients with marrow fibr~sis.'~ It is yet to be established whether splenectomy will promote engraftment in HLA-nonidentical or unrelated Uansplants. A recent study in dogs receiving DLAnonidentical marrow found no significant influence of splenectomy on rates of graft failure.28
In summary, our study showed no significant influence of splenectomy on late posttransplant infections, acute or chronic GVHD, or overall survival. There was no evidence that splenectomy decreased recurrence of CML. Rather, both splenomegaly and splenectomy were associated with a significant increase in the risk of posttransplant relapse. Accordingly, although pretransplant splenectomy may be of value in individual patients in whom the spleen might complicate the immediate course of transplant, there is no evidence that pretransplant splenectomy with the aim of reducing tumor burden results in the desired decrease in leukemic relapse after transplant.
